Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleIMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
dc.contributor.authorLecour, Sandrine
dc.contributor.authorAndreadou, Ioanna
dc.contributor.authorBøtker, H.E.
dc.contributor.authorDavidson, Sean M.
dc.contributor.authorHeusch, Gerd
dc.contributor.authorRuiz-Meana, Marisol
dc.contributor.authorSchulz, Rainer
dc.contributor.authorZuurbier, Coert J.
dc.contributor.authorFerdinandy, Peter
dc.contributor.authorHausenloy, Derek J.
dc.contributor.authorAdamovski, P.
dc.contributor.authorBatirel, S.
dc.contributor.authorBarteková, M.
dc.contributor.authorBertrand, L.
dc.contributor.authorBeauloye, C.
dc.contributor.authorBiedermann, D.
dc.contributor.authorBorutaite, V.
dc.contributor.authorChlopicki, S.
dc.contributor.authorDambrova, M.
dc.contributor.authorDavidson, Sean M.
dc.contributor.authorDevaux, Y.
dc.contributor.authorDi Lisa, F.
dc.contributor.authorDjuric, D.
dc.contributor.authorErlinge, D.
dc.contributor.authorFalcao-Pires, I.
dc.contributor.authorGalatou, E.
dc.contributor.authorGarcia-Sosa, A.
dc.contributor.authorGirao, H.
dc.contributor.authorGiricz, Z.
dc.contributor.authorGyongyosi, M.
dc.contributor.authorHausenloy, Derek J.
dc.contributor.authorHealy, D.
dc.contributor.authorJakovljevic, V.
dc.contributor.authorJovanic, J.
dc.contributor.authorKararigas, G.
dc.contributor.authorKerkal, R.
dc.contributor.authorKolar, F.
dc.contributor.authorKwak, B.
dc.contributor.authorLeszek, P.
dc.contributor.authorLiepinsh, E.
dc.contributor.authorLonborg, J.
dc.contributor.authorLongnus, S.
dc.contributor.authorMarinovic, J.
dc.contributor.authorMuntean, D.M.
dc.contributor.authorNezic, L.
dc.contributor.authorOvize, M.
dc.contributor.authorPagliaro, P.
dc.contributor.authorDa Costa Gomes, C.P.
dc.contributor.authorPernow, J.
dc.contributor.authorPersidis, A.
dc.contributor.authorPischke, S.E.
dc.contributor.authorPodesser, B.
dc.contributor.authorPoto?njak, I.
dc.contributor.authorPrunier, F.
dc.contributor.authorRavingerova, T.
dc.contributor.authorSerban, A.
dc.contributor.authorSlagsvold, K.
dc.contributor.authorvan Royen, N.
dc.contributor.authorTuran, B.
dc.contributor.authorVendelin, M.
dc.contributor.authorWalsh, S.
dc.contributor.authorZidar, N.
dc.contributor.authorZuurbier, Coert J.
dc.contributor.authorYellon, D.
dc.contributor.authoron behalf ofthe European Union-CARDIOPROTECTION COST ACTION CA16225.
dc.identifier.citationLecour, Sandrine, Andreadou, Ioanna, Bøtker, H.E., Davidson, Sean M., Heusch, Gerd, Ruiz-Meana, Marisol, Schulz, Rainer, Zuurbier, Coert J., Ferdinandy, Peter, Hausenloy, Derek J., Adamovski, P., Batirel, S., Barteková, M., Bertrand, L., Beauloye, C., Biedermann, D., Borutaite, V., Chlopicki, S., Dambrova, M., Davidson, Sean M., Devaux, Y., Di Lisa, F., Djuric, D., Erlinge, D., Falcao-Pires, I., Galatou, E., Garcia-Sosa, A., Girao, H., Giricz, Z., Gyongyosi, M., Hausenloy, Derek J., Healy, D., Jakovljevic, V., Jovanic, J., Kararigas, G., Kerkal, R., Kolar, F., Kwak, B., Leszek, P., Liepinsh, E., Lonborg, J., Longnus, S., Marinovic, J., Muntean, D.M., Nezic, L., Ovize, M., Pagliaro, P., Da Costa Gomes, C.P., Pernow, J., Persidis, A., Pischke, S.E., Podesser, B., Poto?njak, I., Prunier, F., Ravingerova, T., Serban, A., Slagsvold, K., van Royen, N., Turan, B., Vendelin, M., Walsh, S., Zidar, N., Zuurbier, Coert J., Yellon, D., on behalf ofthe European Union-CARDIOPROTECTION COST ACTION CA16225. (2021-09-13). IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Research in Cardiology 116 (1) : 52. ScholarBank@NUS Repository.
dc.description.abstractAcute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit. © 2021, The Author(s).
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.rightsAttribution 4.0 International
dc.sourceScopus OA2021
dc.subjectDrug development
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.sourcetitleBasic Research in Cardiology
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1007_s00395-021-00893-5.pdf747.82 kBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons